Umbilical cord lining stem cell treatment for FSHD

Inclusion Criteria:

* Participants will be ≥15 years old.
* Diagnosis of genetically confirmed FSHD 1 or FSHD 2.
* Participants should have a Ricci clinical severity score of ≥1.5 (range is out of 0-10), at screening, and must be independently ambulatory at the time of the study.
* Participant will have the ability to comply with the requirements of the study, including MRI.
* All participants of reproductive age/capacity will be required to use adequate contraception, defined as two forms of highly effective contraceptives, with any partners during the study period and for at least three months beyond the study period for safety.
* Participant will have the ability to understand and provide written informed consent.
* For those participants who are on drug(s) or supplements that may affect muscle function, as determined by the Investigator, participants must be on a stable dose of that drug(s) or supplement for at least 3 months prior to the first dose of study drug and remain on that stable dose for the duration of the study.

  * This includes the following drug category: Immunomodulatory agents, including targeted biological therapies.
  * Exception is rapamycin. (See Exclusion Criteria #10.)
* Current and up-to-date immunizations.
* No contraindications to MRI.
* Hematocrit of ≤ 50%
* Prostate-specific antigen ≤ 4.0 ng/mL (or ≤ 3.0 ng/mL if the participant has a first-degree relative with prostate cancer)
* Fasting blood glucose \<126 mg/dL

Exclusion Criteria:

* Hypersensitivity to study product components including history of hypersensitivity to dimethyl sulfoxide (DMSO).
* Active cancer or prior diagnosis of cancer within the past year (patients with basal and squamous cell cancer of skin will not be excluded).
* Any other condition that, in the judgment of the Investigator or Sponsor, would be a contraindication to enrollment, study product administration, or follow-up.
* Treatment with an investigational product within three months prior to randomization.
* Known active opportunistic or life-threatening infections including Human Immunodeficiency virus (HIV) and hepatitis B or C.
* Known active or inactive tuberculosis infection.
* Use of a product that putatively enhances muscle growth or activity on a chronic basis within 4 weeks before baseline
* Orally administered cytochrome P450 (CYP3A4) substrates and multidrug and toxin extrusion (MATE) and organic anion transporter (OAT)3 substrates are not permitted as concomitant therapy. In case of prior use, wash out period will need to be evaluated by investigator.
* Statin treatment initiation or significant adjustment to statin regimen within 3 months before baseline (stable, chronic statin use is permissible).
* Rapamycin treatment within 3 months before baseline.
* Evidence of an alternative diagnosis other than FSHD or a coexisting myopathy or dystrophy, based on prior muscle biopsy or other available investigations.
* Muscle biopsy within 30 days before baseline.
* A systolic blood pressure over 160 or a diastolic pressure over 100
* Heavy alcohol use (greater than 50g/day)
* Current testosterone or HGH use
* Current use of medications that interfere with the growth hormone or gonadal endocrine axis.
* Pregnant of lactating participants.
* Concomitant severe cardiac, pulmonary disease, active infection, or other conditions that preclude assessment of safety and efficacy of the study product.
* Anticipated need for surgery during the trial period.
* A history of prevalent noncompliance with medical therapy.
* Recipient of an organ transplant.
* Neutropenia (absolute neutrophil count \<1,800/mm\^3 \[or \<1,000/mm\^3 in African-American participants\]).
* Severe impairment in renal function (estimated glomerular filtration rate \<30 ml/min/1.73m\^2).
* Recent of planned use of vaccination with live attenuated viruses.
* Condition that would impair an assessment of muscle strength, including neurological disorders such as Parkinson's disease or severe musculoskeletal condition.